Sign In
Buy QDEL
$13.60
+0.310 (+2.33%)
At Close: Jun 03, 2026
Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know
06:55pm, Thursday, 08'th Apr 2021
Quidel (QDEL) closed the most recent trading day at $128.33, moving -1.47% from the previous trading session.
Quidel's over-the-counter Covid test receives emergency use authorization from FDA
05:11pm, Monday, 05'th Apr 2021
Quidel CEO Douglas Bryant joins 'Closing Bell' to discuss his company's new Covid-19 test, which is available to individuals without a prescription, provided they agree to test twice within 24-36 hour
3 Stocks That Represent Potential Bargains
04:33pm, Sunday, 04'th Apr 2021
As of April 1, the three stocks below appear to be undervalued by the market as their price-earnings ratios without non-recurring items stand below 20 while their price-earnings to growth ratios are n
Coronavirus testing: Quidel receives EUA from FDA for swab-based COVID-19 tests
03:48pm, Friday, 02'nd Apr 2021
Yahoo Finance's Kristin Myers and Anjalee Khemlani spoke to Quidel CEO Douglas Bryant about receiving emergency use authorization from the FDA for the company's swab-based COVID-19 tests.
Quidel's Sofia® SARS Antigen Test Receives Emergency Use Authorization for Screening Use With Serial Testing
08:02pm, Thursday, 01'st Apr 2021
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems,
Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know
06:56pm, Thursday, 01'st Apr 2021
Quidel (QDEL) closed at $130.31 in the latest trading session, marking a +1.86% move from the prior day.
Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing
11:30pm, Wednesday, 31'st Mar 2021
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems,
Quidel's QuickVue® At-Home OTC COVID-19 Test Receives Emergency Use Authorization for Screening Use With Serial Testing
11:00pm, Wednesday, 31'st Mar 2021
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems,
Quidel (QDEL) Gains But Lags Market: What You Should Know
06:58pm, Friday, 26'th Mar 2021
In the latest trading session, Quidel (QDEL) closed at $126.30, marking a +0.13% move from the previous day.
Covid Fatigue Threatens to Derail Once Relevant Quidel
12:12pm, Friday, 26'th Mar 2021
With everyone tired of Covid-19 lockdowns and protocols, it's hard to see QDEL stock as a confident contrarian trade. The post Covid Fatigue Threatens to Derail Once Relevant Quidel appeared first on
4 Reasons I Couldn't Resist Buying This Ridiculously Cheap Coronavirus Stock
06:45am, Saturday, 20'th Mar 2021
Investors are down on Quidel, but there is plenty of reason for optimism.
Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
06:00pm, Thursday, 18'th Mar 2021
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today a
Quidel (QDEL) Dips More Than Broader Markets: What You Should Know
06:56pm, Tuesday, 16'th Mar 2021
Quidel (QDEL) closed the most recent trading day at $138.90, moving -1.53% from the previous trading session.
Quidel Stock Looks Attractive After A 20% Drop
09:00am, Monday, 15'th Mar 2021
The stock price of Quidel Corporation, a manufacturer of diagnostic healthcare products, has seen a large 19% drop over the last ten trading days, while it is down 9% over the last five trading days.
The Pandemic is a Long-Term Factor (NASDAQ: QDEL) (NYSEAMERICAN: APT) (OTC US: BNOW) (NYSE: ABT)
08:01am, Thursday, 04'th Mar 2021
The pandemic won't always be a pandemic, but the virus is going to with us as an endemic part of life. That's the message from a new piece on Reuters.
